Catalyst Pharmaceuticals Inc Stock Research

Market Summary

USD16.58+0.12

Market Closed

0.73%

CPRX Alerts

2 major insider sales recently.
Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)

CPRX Stock Price

CPRX RSI Chart

CPRX Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

21.01

Price/Sales (Trailing)

8.15

EV/EBITDA

13.8

Price/Free Cashflow

15.04

CPRX Price/Sales (Trailing)

CPRX Profitability

EBT Margin

44.08%

Return on Equity

24.78%

Return on Assets

20.09%

Free Cashflow Yield

6.65%

CPRX Fundamentals

CPRX Revenue

Revenue (TTM)

214.2M

Revenue Y/Y

58.6%

Revenue Q/Q

6.14%

CPRX Earnings

Earnings (TTM)

83.1M

Earnings Y/Y

173.62%

Earnings Q/Q

11.97%

Price Action

52 Week Range

6.1522.11

(Low)(High)

Last 7 days

2.9%

Last 30 days

7.2%

Last 90 days

-10.9%

Trailing 12 Months

100%

CPRX Financial Health

Current Ratio

6.18

CPRX Investor Care

Shares Dilution (1Y)

2.20%

Diluted EPS (TTM)

0.75

Peers (Alternatives to Catalyst Pharmaceuticals)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	292.3B	1.4B	-8.63%	14.28%	-145.87	206.43	20.37%	-37.45%
ABBV	282.2B	58.1B	2.64%	1.09%	23.85	4.86	3.30%	2.55%
REGN	87.8B	12.2B	6.65%	17.65%	20.25	7.22	-24.26%	-46.28%
VRTX	81.0B	8.9B	8.19%	20.73%	24.38	9.07	17.91%	41.84%
ALNY	24.8B	1.0B	2.52%	22.68%	-21.95	23.93	22.88%	-32.64%
SRPT	12.1B	933.0M	-5.36%	76.43%	-17.23	12.99	32.93%	-67.99%
UTHR	10.3B	1.9B	-8.55%	24.83%	14.17	5.32	14.88%	52.86%
MID-CAP
MDGL	4.4B	504.0K	-13.23%	146.90%	-14.85	2.5K	-66.53%	-22.12%
RARE	2.8B	363.3M	-12.16%	-44.78%	-3.98	7.75	3.39%	-55.81%
BPMC	2.7B	204.0M	4.26%	-29.57%	-4.84	13.22	13.30%	13.44%
MRTX	2.2B	12.4M	-17.27%	-54.78%	-2.9	172.97	-	-27.34%
SMALL-CAP
CPRX	1.7B	214.2M	7.24%	100.00%	21.01	8.15	52.10%	110.42%
MGNX	442.4M	151.9M	15.09%	-18.62%	-3.69	2.91	96.19%	40.75%
CRBP	30.3M	-	159.64%	1267.83%	-0.72	19.11	-77.61%	7.22%
CYTK	3.3M	94.6M	-18.37%	-4.40%	-0.01	0.03	34.30%	-80.65%

Financials for Catalyst Pharmaceuticals

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	11.7%	214	192	170	154	141
Operating Expenses	4.1%	112	108	98.00	94.00	88.00
S&GA Expenses	2.5%	58.00	57.00	55.00	53.00	50.00
R&D Expenses	-4.3%	20.00	21.00	17.00	17.00	17.00
EBITDA	16.4%	85.00	73.00	60.00	53.00	-
EBITDA Margin	3.5%	0.44*	0.43*	0.39*	0.38*	-
Earnings Before Taxes	23.9%	105	85.00	73.00	60.00	53.00
EBT Margin	3.5%	0.44*	0.43*	0.39*	0.37*	-
Net Income	24.2%	83.00	67.00	54.00	45.00	39.00
Net Income Margin	9.2%	0.35*	0.32*	0.29*	0.28*	-
Free Cahsflow	26.2%	95.00	75.00	64.00	59.00	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	12.8%	376	333	267	247	238
Current Assets	16.1%	321	276	243	221	210
Cash Equivalents	16.5%	298	256	211	178	171
Inventory	-4.6%	7.00	7.00	8.00	8.00	8.00
Net PPE	-4.0%	1.00	1.00	1.00	1.00	1.00
Liabilities	19.2%	75.00	63.00	26.00	27.00	31.00
Current Liabilities	28.9%	58.00	45.00	22.00	23.00	27.00
Shareholder's Equity	11.3%	300	270	241	220	207
Retained Earnings	104.4%	50.00	24.00	2.00	-15.62	-26.31
Additional Paid-In Capital	2.0%	250	246	239	236	233
Accumulated Depreciation	10.4%	0.00	0.00	0.00	0.00	-
Shares Outstanding	1.2%	105	104	103	103	103

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	22.0%	116	95.00	76.00	65.00	60.00
Share Based Compensation	6.1%	8.00	7.00	7.00	6.00	6.00
Cashflow From Investing	2761.6%	9.00	-0.35	-0.22	-11.02	-
Cashflow From Financing	154.9%	2.00	-3.08	-9.17	-9.88	-8.14
Buy Backs	-31.0%	7.00	10.00	15.00	14.00	12.00

Risks for CPRX

What is the probability of a big loss on CPRX?

90.8%

Probability that Catalyst Pharmaceuticals stock will be more than 20% underwater in next one year

67.7%

Probability that Catalyst Pharmaceuticals stock will be more than 30% underwater in next one year.

65.4%

Probability that Catalyst Pharmaceuticals stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CPRX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Catalyst Pharmaceuticals was unfortunately bought at previous high price.

Drawdowns

Returns for CPRX

Cumulative Returns on CPRX

43.0%

10-Year Cumulative Returns

45.5%

7-Year Cumulative Returns

47.3%

5-Year Cumulative Returns

62.7%

3-Year Cumulative Returns

What are the long-term rolling returns for CPRX?

FIve years rolling returns for Catalyst Pharmaceuticals.

Annualized Returns

Which funds bought or sold CPRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-23	MetLife Investment Management, LLC	reduced	-4.92	257,806	939,002	0.01%
2023-03-15	B. Riley Wealth Advisors, Inc.	new	-	475,583	475,583	0.01%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	reduced	-19.96	753,423	5,448,420	0.01%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-25.00	-	5,000	-%
2023-02-28	Voya Investment Management LLC	reduced	-4.28	292,463	1,048,460	-%
2023-02-22	TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY	unchanged	-	172,000	555,000	0.01%
2023-02-21	MACQUARIE GROUP LTD	sold off	-100	-2,424,000	-	-%
2023-02-21	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	added	12,500	4,687	4,687	-%
2023-02-16	GHP Investment Advisors, Inc.	unchanged	-	7,320	22,320	-%
2023-02-15	Steward Partners Investment Advisory, LLC	unchanged	-	488	1,488	-%

Latest Funds Activity

Are funds buying CPRX calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own CPRX

No. of Funds

Catalyst Pharmaceuticals News

Schedule 13G FIlings of Catalyst Pharmaceuticals

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	armistice capital, llc	0%	0	SC 13G/A
Feb 10, 2023	flynn james e	5.65%	5,884,448	SC 13G/A
Feb 09, 2023	vanguard group inc	6.50%	6,768,741	SC 13G
Feb 08, 2023	state street corp	7.57%	7,873,314	SC 13G/A
Jan 26, 2023	blackrock inc.	15.1%	15,690,326	SC 13G/A
Jan 20, 2023	blackrock inc.	15.1%	15,690,326	SC 13G/A
Nov 14, 2022	flynn james e	5.82%	6,060,491	SC 13G
Feb 15, 2022	armistice capital, llc	9.3%	9,572,000	SC 13G/A
Feb 09, 2022	vanguard group inc	4.69%	4,836,313	SC 13G/A
Feb 09, 2022	state street corp	4.90%	5,050,989	SC 13G/A

CPRX Fair Value

Catalyst Pharmaceuticals fair value in different scenarios

The table shows the Fair Value estimates for Catalyst Pharmaceuticals for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	19.69 18.76%	25.51 53.86%	49.11 196.20%	79.84 381.54%	135.24 715.68%
Current Inflation	18.07 8.99%	23.05 39.02%	43.34 161.40%	69.43 318.76%	116.42 602.17%
Very High Inflation	16.05 -3.20%	20.07 21.05%	36.50 120.14%	57.28 245.48%	94.69 471.11%

Historical Catalyst Pharmaceuticals Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Catalyst Pharmaceuticals

View All Filings

Date Filed	Form Type	Document
Mar 31, 2023	8-K	Current Report
Mar 30, 2023	4	Insider Trading
Mar 30, 2023	4	Insider Trading
Mar 24, 2023	4	Insider Trading
Mar 22, 2023	4	Insider Trading
Mar 15, 2023	10-K	Annual Report
Mar 15, 2023	8-K	Current Report
Mar 07, 2023	8-K	Current Report
Feb 17, 2023	4	Insider Trading
Feb 17, 2023	4	Insider Trading

Latest Insider Trading transactions for CPRX

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-29	Del Carmen Jeffrey	acquired	127,063	3.17659	40,000	chief commercial officer
2023-03-29	Del Carmen Jeffrey	sold	-667,810	16.6952	-40,000	chief commercial officer
2023-03-29	GRANDE ALICIA	sold	-835,100	16.702	-50,000	vp, treasurer and cfo
2023-03-29	GRANDE ALICIA	acquired	56,500	1.13	50,000	vp, treasurer and cfo
2023-03-28	GRANDE ALICIA	acquired	45,990	0.79	58,216	vp, treasurer and cfo
2023-03-28	GRANDE ALICIA	sold	-962,786	16.5382	-58,216	vp, treasurer and cfo
2023-03-22	GRANDE ALICIA	sold	-689,528	16.5022	-41,784	vp, treasurer and cfo
2023-03-22	GRANDE ALICIA	acquired	33,009	0.79	41,784	vp, treasurer and cfo
2023-03-20	Elsbernd Brian	sold	-803,450	16.069	-50,000	chief compliance/legal officer
2023-03-20	Elsbernd Brian	acquired	56,500	1.13	50,000	chief compliance/legal officer

About Catalyst Pharmaceuticals

Patrick J. McEnany

www.catalystpharma.com

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CPRX Income Statement

2022-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues:
Total revenues	$ 214,203	$ 140,833	$ 119,073
Operating costs and expenses:
Cost of sales	34,393	21,884	17,039
Research and development	19,789	16,936	16,497
Selling, general and administrative	58,183	49,628	44,234
Total operating costs and expenses	112,365	88,448	77,770
Operating income	101,838	52,385	41,303
Other income, net	2,881	282	587
Net income before income taxes	104,719	52,667	41,890
Income tax provision (benefit)	21,640	13,185	(33,093)
Net income	$ 83,079	$ 39,482	$ 74,983
Net income per share:
Basic	$ 0.8	$ 0.38	$ 0.72
Diluted	$ 0.75	$ 0.37	$ 0.71
Weighted average shares outstanding:
Basic	103,374,606	103,379,349	103,512,913
Diluted	111,375,631	107,795,585	106,242,273
Net income	$ 83,079	$ 39,482	$ 74,983
Other comprehensive income:
Unrealized gain (loss) on available-for-sale securities, net of tax of ($54), $46 and $0, respectively	172	(179)	22
Comprehensive income	83,251	39,303	75,005
Product revenue, net [Member]
Revenues:
Total revenues	213,938	137,997	118,790
License and other revenue [Member]
Revenues:
Total revenues	$ 265	$ 2,836	$ 283

CPRX Balance Sheet

2022-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 298,395	$ 171,445
Short-term investments	0	19,821
Accounts receivable, net	10,439	6,619
Inventory	6,805	7,870
Prepaid expenses and other current assets	5,158	4,351
Total current assets	320,797	210,106
Operating lease right-of-use asset	2,770	3,017
Property and equipment, net	847	959
License and acquired intangibles, net	32,471
Deferred tax assets, net	18,736	23,697
Deposits	9	9
Total assets	375,630	237,788
Current Liabilities:
Accounts payable	3,975	2,768
Accrued expenses and other liabilities	53,613	24,295
Total current liabilities	57,588	27,063
Operating lease liability, net of current portion	3,557	3,894
Other non-current liabilities	14,064
Total liabilities	75,209	30,957
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at December 31, 2022 and 2021	0	0
Common stock, $0.001 par value, 200,000,000 shares authorized; 105,263,031 shares and 102,992,913 shares issued and outstanding at December 31, 2022 and 2021, respectively	105	103
Additional paid-in capital	250,430	233,186
Retained earnings (accumulated deficit)	49,862	(26,310)
Accumulated other comprehensive income (loss)	24	(148)
Total stockholders' equity	300,421	206,831
Total liabilities and stockholders' equity	$ 375,630	$ 237,788